Debra Morris
Adult Health · Overland Park, KSNPI 1316108566
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $302 and has fallen 60.7% since, to $119 in 2025.
Across 58 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$206
- Novo Nordisk$107
- Alkermes, Inc.$93
- Johnson & Johnson$93
- AstraZeneca$60
- Boston Scientific$54
- plus $402 from 17 others
What the payments were for
- Food & beverage$1,015100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $206 |
| Novo Nordisk | 6 | $107 |
| Alkermes, Inc. | 4 | $93 |
| Johnson & Johnson | 5 | $93 |
| AstraZeneca(2 entities) | 4 | $60 |
| Boston Scientific | 2 | $54 |
| Amgen | 3 | $53 |
| Bayer | 3 | $43 |
| Eisai Inc. | 2 | $37 |
| Abbott | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Lilly USA, LLC | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Indivior Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| GSK | 1 | $12 |
| Paratek Pharmaceuticals, Inc. | 1 | $11 |
| Endogastric Solutions, Inc | 2 | $7 |
How this compares
$1,015 in reported general payments places this provider in the 65th percentile of 155 adult health providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 11 | $886 |
| Quetiapine Fumarate | 19 | $358 |
| Lamotrigine | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other adult health in Overland Park
- Lauren FieldsOverland Park$12K
- Tina LegaultOverland Park$12K
- Monica PfeifferOverland Park$7K
- Amy RiederOverland Park$6K
- Paige BudzinskiOverland Park$4K
- Mary MartinOverland Park$2K
- Carla ShepardOverland Park$2K
- Jill SoenenOverland Park$1K
- Carrie EnglertOverland Park$1K
- Christina SchmidtOverland Park$968
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.